From TheNationalPulse.com…
Pfizer is about to buy Arena Pharmaceuticals for $6.7 billion. Arena is a biopharmaceutical company focused in part on cardiovascular and inflammatory medicines to a global patient cohort.
A majority of mainstream news outlets have focused their reportage on Arena’s bowel disease treatment, while failing to mention the firm’s cardiovascular research.
Utah-based Arena has existing partnerships with United Therapeutics, who focus their research efforts on pulmonary arterial hypertension. Pfizer’s decision to acquire Arena and their relationship with United Therapeutics is certain to net the company more in return than the bowel disease treatment touted by the corporate press.
